RSA-renewed Blincyto and PVA Xalkori pricing reduced

MOHW to revise the list of reimbursed drugs and upper limit pricing to enforce from January

Xgeva voluntarily lessens pricing by 1.9% with expanded indication

Amgen Korea’s Blincyto 35 μg (blinatumomab) renewed the risk sharing agreement (RSA) with the National Health Insurance Service (NHIS) prior to its termination.

 

As a result, the pricing was lowered by 11.4 percent, effective from next month.

 

With surging sales, Pfizer Pharmaceutical Korea’s Xalkori (crizotinib) is now categorized as a subject for price-volume agreement (PVA) negotiation and has agreed to bring down the pricing of each dose by 2.3 percent.

 

The pharmaceutical industry sources reported, the South Korean Ministry of Health and Welfare (MOHW) is working on the said revisions for the ‘List of Reimbursed Drugs and Upper Limit Pricing.’ The finalized revision would be enforced from Jan.

 

1.

 

Apparently, Amgen Korea has negotiated with NHIS on the RSA renewal and settled on lowering the pricing by 11.4 percent.

 

From next year, the existing price of 2,223,503 won per vial would be reduced to 1.97 million from next year.

 

Newly categorized as a PVA Type Ga (가), Pfizer Pharmaceutical Korea’s Xalkori capsule has undergone pricing negotiation.

 

A new drug listed through a pricing negotiation would be would be categorized as a Type Ga drug, if its total claim of the same product lineups exceeds over 30 percent of the projected claim decided during the pricing negotiation.

 

And then, NHIS and the pharmaceutical company would negotiate and settle on a reduced pricing.

 

The same product lineups mentioned above means a series of pharmaceutical items with identical supplier’s name, administration route, substance and form.

 

The pricing of respective doses of the product would be lessened by 2.3 percent—previously 47,225 won to be 46,139 won for 200 mg, and previously 53,364 won to be 52,137 won for 250 mg.

 

On the contrary, a company voluntarily chose to decrease the pricing as the drug has expanded its reimbursement scope, or the indication.

 

Drug pricing reduction for expanded indication system preemptively reduces the pricing of a drug with new reimbursed indication by taking account of the projected increase or additional claim.

 

Applying the change, Amgen Korea’s Xgeva injection’s (denosumab) existing price of 249,800 won would be brought down to 245,054 won by 1.9 percent.